SCIENCE

Sinclair targets GLP-1 blindness in new human gene therapy trials

Wednesday, April 29, 2026 · from 1 podcast, 2 episodes

David Sinclair’s lab begins human trials using OSK gene therapy to reverse blindness, a rare side effect of popular GLP-1 drugs.
The team has an AI-screened, pill-based ‘age reversal’ cocktail in development to democratize million-dollar gene therapies.
Private ‘patronage’ funding now powers the lab’s radical experiments after Harvard grant cuts stalled academic progress.

David Sinclair is treating science like a startup. Days after a new episode aired, his lab injected the first human patient with OSK genes - three of the four Yamanaka factors - in an attempt to reverse cellular aging and restore vision. The target is a specific form of sudden blindness linked to GLP-1 weight-loss drugs, a pivot that puts his epigenetic reprogramming work directly against a modern pharmaceutical side effect.

Sinclair told Peter Diamandis on Moonshots that roughly 20,000 to 30,000 Americans annually develop NAION, a type of optic nerve stroke. His lab’s therapy, code-named ER100, aims to reset the age of eye cells, having already regrown motor neurons in animals. “If biological age can be reset in the optic nerve, the blindness caused by these drugs might not be permanent,” Sinclair argued.

“The era of theoretical longevity is ending.”
- David Sinclair, Moonshots with Peter Diamandis

Success in the eye trials would instantly broaden the scope. Sinclair’s team has already reversed aging in mouse brains, kidneys, and muscles using the same OSK approach. He views the current tissue-by-trial process as an FDA-imposed stepping stone toward a systemic treatment. The ultimate goal is a cheap, daily pill.

To get there, the lab is deploying autonomous AI systems. One agentic model named Cadence analyzed transcriptomic data and identified biological age markers humans had missed. Another screens billions of molecules in silico to find chemicals that mimic the OSK effect; a proof-of-concept cocktail has already reversed skin cells from a 92-year-old donor to a 20-year-old state. Sinclair believes a pill could enter human trials within months and eventually cost pennies a dose.

“This shift highlights a growing frustration with the NIH and academic peer-review systems.”
- Peter Diamandis, Moonshots with Peter Diamandis

This acceleration is fueled by a private funding revolt. After Harvard political friction cut his government grants, Sinclair and Diamandis launched ‘Friends of Sinclair Lab’ (FOSL), a patronage model that raised $6 million from 70 individuals. The model lets the lab move from idea to experiment in weeks, recently funding a project to cure a lab member’s kidney failure after traditional avenues failed. It’s a template for bypassing what they see as a broken, risk-averse grant system.

Sinclair projects that 2026 could be the year human age reversal is definitively proven. He rejects the concept of a biological lifespan limit, arguing the goal is ‘longevity escape velocity.’ The immediate test is whether a reset button for the eye works - and if it does, the clock starts ticking for every other aged tissue.

Longevity Health Biology

Peter Diamandis

Source Intelligence

- Deep dive into what was said in the episodes

Moonshots with Peter Diamandis

David Sinclair: The GLP-1 Side Effect No One Talks About, What AI Found in His Lab, and Reversing Blindness | Q&A EP #251 • Apr 28

David Sinclair says emerging data shows GLP-1 drugs benefit the heart and brain beyond weight loss, but notes a rare but serious side effect: about 20,000-30,000 people in the US annually develop sudden blindness, called NAION.
Sinclair states that AI accelerates his lab's work exponentially, enabling drug design by screening billions of molecules and classifying millions of cells as young or old within minutes.
Sinclair cites his own father's health as evidence that lifestyle can override poor genetics, noting his Ashkenazi Jewish ancestors typically died in their 70s.
Sinclair argues mindset is a powerful longevity factor, citing a National Academy of Sciences study that found optimists live 15% longer than pessimists.
Sinclair explains his xenohormesis hypothesis: stressed plants produce polyphenols that signal adversity, activating longevity pathways like SIRT1. He recommends eating colorful vegetables like broccolini.
Sinclair says recent research challenges the old view that genetics determines only 10-15% of lifespan, suggesting the influence may be closer to 50%, but emphasizes at least half of lifespan remains under personal control.
Peter Diamandis frames genetics' role: lifestyle determines health for the first 70-80 years, genetics dominate from 80 to 110, and emerging therapeutics aim to overcome genetic limits.
Sinclair cites evidence that nattokinase is the most natural and powerful method to reverse atherosclerosis, while lowering LDL with drugs like PCSK9 inhibitors can also have reversal effects.
Sinclair details his lab's OSK gene therapy, showing it activates telomerase to lengthen telomeres and is being tested to reverse blindness from NAION, ALS, and macular degeneration in animal models.
Sinclair, prompted by his wife Serena, is now studying the mind-body connection, citing a paper showing brain nerve manipulation affects gut immunity and having a student research sensory nerve rejuvenation.
Sinclair advises investors in longevity biotech to prioritize team reputation and track record, cash runway, and clinical stage, noting capital deficiency is the number one cause of company mortality.
Sinclair references decades of work by Dr. Bhasin showing testosterone does not extend lifespan but prevents falls and supports metabolic health, while clarifying that hormone replacement for women is now considered safe.
Sinclair emphasizes the need to stress the body in an abundance-driven world, advocating for saunas, red light therapy, avoiding plastics, and improving indoor air and water quality.

Health Longevity Biology Models Agents

David Sinclair on the Longevity Pill, Age Reversal Timelines, and Updated Protocols | EP #250 • Apr 27

David Sinclair's lab is days away from the first human epigenetic reprogramming trial, using a subset of three Yamanaka genes (OSK) in the eye of a patient to cure blindness, following successful mouse and monkey trials.
The epigenetic reprogramming technology shows benefits across various tissues in mice, including brain age reversal, memory improvement, and positive effects on motor neurons (ALS models), immune system, muscle, kidney, liver, skin, and joints.
Current human trials for targeted gene therapies, using adeno-associated viruses (AAV) for OSK delivery, typically cost between $500,000 and $2 million per treatment, but Sinclair aims for widespread, affordable application.
The Sinclair Lab developed a small molecule cocktail using AI screening, achieving proof of concept in reversing skin cells from 92-year-olds to a 20-year-old state. This cocktail aims for human clinical trials within months, with potential costs of a few cents per pill at scale.
David Sinclair believes there is no biological or physical law limiting human lifespan, suggesting it's possible to live hundreds or thousands of years by repeatedly resetting cells, akin to how the Wright Brothers’ flight opened possibilities beyond early expectations.
Peter Diamandis initiated the 'Friends of Sinclair Lab' (FOSL) to provide private, direct funding to David Sinclair's research after his government grants, totaling $1-3 million annually, were cut. FOSL has since raised approximately $6 million in annual support from around 70 members.
Sinclair projects that age reversal in humans could be definitively proven as possible as early as 2026, marking a pivotal moment in longevity research.
David Sinclair's personal longevity protocol includes resveratrol (taken with oil for absorption), NMN, and glucose-lowering medications like metformin (1 gram daily) or berberine. He also takes nattokinase (10,000 units daily), which has shown to reverse arterial plaque.
Sinclair emphasizes dietary adjustments like a mostly vegan diet, avoiding processed carbohydrates, and significantly reducing alcohol consumption due to new data linking even one daily glass to smaller brain size. He monitors health with carotid ultrasounds, preferring them over radiation-emitting CT scans.
Maintaining social connections, reducing stress through practices like meditation, and ensuring adequate sleep are crucial for longevity, as loneliness and chronic tension accelerate aging and negatively impact biomarkers like blood pressure and cholesterol.

Longevity Biology Health Startups